培美曲塞联合顺铂一线治疗晚期非小细胞肺癌34例临床疗效和安全性观察

目的：观察培美曲塞联合顺铂一线治疗晚期非小细胞肺癌（NSCLC）的近期疗效及毒副反应。方法34例晚期肺癌患者采用培美曲塞联合顺铂治疗方案，其中培美曲塞500mg/m2，顺铂75mg/m2。结果34例患者有效率（CR＋PR）为38．24％，疾病控制率（CR＋PR＋SD）为79．4％，主要毒性反髓抑应为骨制，消化道反应，皮疹等。结论培美曲塞联合顺铂一线治疗晚期非小细胞肺癌疗效较好，毒性反应较低，值得临床推广使用。

An investigation on clinical effect and safety of pemetrexed combined with cisplatin advanced non small ;cell lung cancer of 34 cases

Objective To investigate the clinical effect and safety of pemetrexed joint with cisplatin for the patients with advanced non-small cell lung cancer （ NSCLC） .Methods 34 patients with NSCLC received a treatment program with pemetrexed and cisplatin , the dose of pemetrexed was 500mg/m2, and cisplatin was 75mg/m2 .Results The efficiency （ CR＋PR） of 34 patients was 38.24%, the disease control rate （ CR＋PR＋SD） was 79.4%, and the mainly adverse reactions were bone marrow suppression , gastrointestinal reactions , skin rash.Conclusions The pemetrexed joint with cisplatin has a clear efficacy and slight toxicity for NSCLC , worthy of clinical use .